(PRWEB) January 02, 2013
Neurological Wellness Center began holding perispinal injection technique training courses in the spring of 2011. Since then physicians, nurses and lay caregivers have come from around the world to their Center in Managua Nicaragua for individualized instructional courses teaching this procedure. Presently Neurological Wellness Center remains the only institution in the world teaching this perispinal Enbrel injection procedure. For more information about Neurological Wellness Center’s perispinal injection courses, visit: http://reversealzheimersnow.com.
For many, flying to Managua Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez M.D., created Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 25-page e-book are now available online at http://www.neurological-recovery-guide.com.
Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.
This study published December 2012 in the Journal CNS Drugs and available online: http://www.ncbi.nlm.nih.gov/pubmed/23100196, systematically examined the clinical responses of 629 patients afflicted by stroke or traumatic brain injury following the perispinal administration of Enbrel (Etanercept). The mean age of the stroke patients was 65.8 years. The mean interval between stroke and perispinal Enbrel treatment (PSE) was 42.0 months. The mean age of the traumatic brain injury (TBI) patients was 34.7 years. The mean interval between TBI and PSE treatment was 115 months.
Comprehensive pre-treatment and post-treatment assessments were made, with particular attention given to motor function, walking, pain, sensation, cognition and mood. A variety of standardized instruments were utilized in making these assessments. Neurological Wellness Center finds the results of this study to be extraordinarily noteworthy, not simply for the degree of the improvements observed but also for the extent of improvements across many areas of assessment. Equally striking was the rapidity of the improvement. Observations such as “rapid motor improvement beginning within minutes” was routinely observed in both post-stroke and the TBI patients” are ubiquitous throughout this observational study. The fact that the mean interval between stroke and PSE was 42.0 months and TBI and PSE 115 months makes these results even more remarkable. These results herald a new paradigm of understanding stroke and traumatic brain injury; whereby a self-perpetuating cascade of inflammation is produced in response to the trauma and the on-going inflammation contributes substantially to the impairments people experience. Once this inflammation is attenuated, significant recovery of physical and cognitive function becomes a reality these people experience often for the first time in years.
Neurological Wellness Center laments that this off-label use of the drug Enbrel has the potential to help countless millions of people in their everyday lives yet is so seldom utilized. We call on the U.S. Food and Drug Administration to repurpose Enbrel for the treatment of Alzheimer’s disease, stroke and traumatic brain injury. We join with Terry Pratchett and hundreds of physicians worldwide in calling on the U.S. Food and Drug Administration (FDA) to immediately initiate the steps necessary to repurpose Enbrel for the treatment of Alzheimer’s disease, stroke and traumatic brain injury. This study by Dr. Edward Tobinick shows unequivocally in a clear and convincing way that perispinal Enbrel treatment can ameliorate the impairments countless millions of people experience due to stroke and traumatic brain injury. To view video of before and after PSE treatment of alzheimer’s disease, stroke and TBI visit: http://reversealzheimersnow.com/.
Common to Alzheimer’s, stroke and traumatic brain injury is excess inflammation in the brain. It is this self-perpetuating inflammation cascade that contributes to many of the impairments people experience.
Enbrel is a powerful anti-inflammatory agent. This drug is a fusion of two proteins that occur naturally in the human body. Enbrel (etanercept) received FDA approval in 1998 as a treatment of rheumatoid arthritis. The broad therapeutic role of Enbrel is based on the fact that TNF-alpha is the master regulator of the inflammatory response in many organ systems throughout the body. Enbrel is a large protein molecule that binds to TNF-alpha effectively neutralizing and down regulating the body’s inflammatory response.
The perispinal injection itself, as we teach it is extremely safe. The injection is a simple subcutaneous injection performed with a fine gauge half-inch needle. This injection is a unique form of subcutaneous injection. The precise location of the injection site and the proper positioning of the person receiving the injection are critical for successful administration. This procedure is illustrated in step-by-step fashion in the 24-minute video and 25-page e-book.
Safety issues pertaining to the drug Enbrel are covered on the Enbrel.com website. Although Enbrel is a widely used drug with over 400,000 Americans self-injecting it weekly, it is not suitable for everyone. The Enbrel dosing schedule we counsel in our on-line course is generally quite low compared to the maximums recommended by Amgen/Pfizer for the treatment of rheumatoid plaque psoriasis.
The general counsel is to initiate perispinal Enbrel treatment as soon as possible after suffering a stroke or traumatic brain injury. Oral minocycline is generally prescribed as a concomitant therapy. Minocycline is an antibiotic with an excellent safety record and, like Enbrel it reduces the effects of excess TNF-alpha in the brain. Minocycline has the capacity to enhance the efficacy of perispinal Enbrel treatments. All treatment is initiated on a trial basis. There is a wide range of outcomes. Some clients have experienced dramatic life-changing recoveries even when treatment was begun years after the stroke or traumatic brain injury.
Enbrel was developed to treat various inflammatory diseases by binding to TNF-alpha, effectively neutralizing its ability to act on cell membranes. Perispinal Enbrel treatment has a rapid effect reversing cognitive impairment and validating the role excess TNF-alpha plays in the disease processes of Alzheimer’s, stroke and traumatic brain injury. Enbrel’s long half-life (70 to 132 hours) enables a series of treatments to produce sequential progressive improvements in cognitive function that can be maintained long term. The standard method for delivering CNS-active medication to the brain is via the blood. Enbrel, a large protein molecule, is unable to cross the blood-brain barrier. A subcutaneous perispinal injection to the fatty tissues at the back of the neck enables etanercept to enter the brain by lymph and venous drainage assisted by gravity.”
To learn more about perispinal Enbrel as a treatment for Alzheimer’s, stroke or traumatic brain injury and to purchase this $49 on-line course, please visit: http://www.neurological-recovery-guide.com.